Cell line and patient-derived xenograft models reveal elevated CDCP1 as a target in high-grade serous ovarian cancer

BACKGROUND: Development of targeted therapies for high-grade serous ovarian cancer (HGSC) remains challenging, as contributing molecular pathways are poorly defined or expressed heterogeneously. CUB-domain containing protein 1 (CDCP1) is a cell-surface protein elevated in lung, colorectal, pancreas,...

Descripción completa

Detalles Bibliográficos
Autores principales: Harrington, Brittney S, He, Yaowu, Davies, Claire M, Wallace, Sarah J, Adams, Mark N, Beaven, Elizabeth A, Roche, Deborah K, Kennedy, Catherine, Chetty, Naven P, Crandon, Alexander J, Flatley, Christopher, Oliveira, Niara B, Shannon, Catherine M, deFazio, Anna, Tinker, Anna V, Gilks, C Blake, Gabrielli, Brian, Brennan, Donal J, Coward, Jermaine I, Armes, Jane E, Perrin, Lewis C, Hooper, John D
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Translational Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4815773/
https://www.ncbi.nlm.nih.gov/pubmed/26882065
http://dx.doi.org/10.1038/bjc.2015.471

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4815773/
https://www.ncbi.nlm.nih.gov/pubmed/26882065
http://dx.doi.org/10.1038/bjc.2015.471

Ejemplares similares